eNeura Alternatives

eNeura's SAVI Dual uses single-pulse transcranial magnetic stimulation for migraine treatment through a prescription-based access model. For people comparing non-invasive migraine neuromodulation options, the broader device category now includes FDA-cleared technologies with different access requirements, treatment formats, device placements, and ownership models.

Key Takeaways

• Cefaly offers a strong access advantage: Cefaly is an FDA-cleared e-TNS migraine relief device available without a prescription in the U.S
• Cefaly combines acute and preventive adult migraine indications: FDA documentation lists Cefalyl for over-the-counter use for the acute treatment of migraine with or without aura in patients 18 years of age or older and the prophylactic treatment of episodic migraine in patients 18 years of age or older
• Device formats differ by placement and control style: Cefaly is forehead-based, Nerivio is upper-arm based, gammaCore is applied at the neck, Relivion MG is a headband-style device, HeadaTerm 2 is forehead-based, and eNeura SAVI Dual is applied at the back of the head
• Access models vary: Cefaly and HeadaTerm 2 are OTC options in the U.S.; eNeura SAVI Dual, Nerivio, gammaCore, and Relivion MG are prescription-based devices
• Total cost depends on access model and supplies: Cefaly uses a one-time device purchase plus replacement electrodes, while some alternatives use prescription, refill, subscription, or program-based access models

Understanding Non-Invasive Neuromodulation for Migraine

Non-invasive neuromodulation devices use external electrical or magnetic stimulation to interact with nerve pathways involved in migraine. The devices in this category are not identical. They differ in mechanism, placement, indications, access requirements, treatment time, and safety information.

Common device categories include:

• External trigeminal nerve stimulation (e-TNS): Used by Cefaly, this approach targets branches of the trigeminal nerve through an electrode placed on the forehead
• Single-pulse transcranial magnetic stimulation (sTMS): Used by eNeura SAVI Dual, this approach delivers magnetic pulses at the back of the head
• Remote electrical neuromodulation (REN): Used by Nerivio, this approach delivers stimulation through an upper-arm wearable
• Non-invasive vagus nerve stimulation (nVNS): Used by gammaCore, this approach delivers stimulation at the neck
• External combined occipital-trigeminal neurostimulation: Used by Relivion MG, this approach uses a headband-style device to stimulate trigeminal and occipital nerve branches
• Transcutaneous electrical nerve stimulation for migraine prophylaxis: Used by HeadaTerm 2, this approach delivers stimulation through a forehead-based device format

Non-invasive neuromodulation devices are FDA-cleared for specific migraine-related indications. Each device should be reviewed according to its own labeling, access requirements, contraindications, and safety information.

1) Cefaly

Comparison Fit: People comparing an OTC, forehead-based e-TNS device with both acute and preventive adult migraine indications

Access: Available without a prescription in the U.S.

Treatment Format: Forehead-based external trigeminal nerve stimulation with Acute and Prevent programs

Cefaly is an FDA-cleared external trigeminal nerve stimulation device for migraine. FDA documentation for Cefaly lists over-the-counter indications for the acute treatment of migraine with or without aura in patients 18 years of age or older and for the prophylactic treatment of episodic migraine in patients 18 years of age or older.

Cefaly’s e-TNS technology targets the trigeminal nerve, the primary pathway for migraine pain. The trigeminal nerve is located under the skin of the forehead, and the device stimulates nerve endings through an electrode positioned on the forehead, between and just above the eyebrows. Cefaly’s how it works page describes this forehead-based trigeminal nerve stimulation approach.

What Makes It Stand Out

Cefaly stands out because it combines OTC access, a forehead-based e-TNS format, two fixed treatment programs, and a one-time device ownership model. Cefaly's Acute program is designed as a 60-minute session, while its Prevent program is designed as a 20-minute daily session.

Cefaly also supports practical use through the Cefaly Migraine Relief app, which offers treatment controls, therapy tracking, migraine logging, and wearable integrations where available. The device can also operate as a standalone device, which distinguishes it from options that require smartphone control.

Cefaly also offers support features that strengthen its practical positioning: free one-on-one coaching, HSA/FSA eligibility, VA coverage information, and a satisfaction guarantee. For products purchased directly fromthe official website, Cefaly’s return policy states that customers who are not satisfied may return the product within 90 calendar days of the product delivery date.

Cefaly Clinical Evidence

Cefaly’s evidence base is specific to Cefaly and e-TNS. Its clinical studies summarizes research across acute and preventive migraine use, including studies evaluating pain reduction, migraine-day reduction, and acute medication intake in Cefaly users. This evidence should be interpreted in relation to Cefaly’s own device, labeling, and instructions for use.

2) Nerivio

Comparison Fit: People comparing an upper-arm device format and prescription-based access

Access: Prescription required

Treatment Format: Smartphone-controlled remote electrical neuromodulation device worn on the upper arm

Nerivio uses remote electrical neuromodulation through an upper-arm wearable. This format differs from forehead-based devices because the device is worn away from the head, which may be an important practical consideration for people comparing device placement during migraine attacks.

What Makes It Stand Out

Nerivio stands out for upper-arm placement, smartphone-controlled treatment format, and an age indication that includes patients 8 years of age and older. Its official website describes acute and/or preventive treatment of migraine with or without aura in patients 8 years of age or older, and it is a prescription-use, self-administered device for home use.

3) gammaCore Sapphire

Comparison Fit: People comparing a neck-applied vagus nerve stimulation format and prescription-based access

Access: Prescription required

Treatment Format: Handheld non-invasive vagus nerve stimulation device applied at the neck

gammaCore Sapphire uses non-invasive vagus nerve stimulation rather than trigeminal nerve stimulation. This makes it mechanically different from Cefaly, Nerivio, Relivion MG, HeadaTerm 2, and eNeura SAVI Dual.

What Makes It Stand Out

gammaCore stands out because its official FAQ lists FDA-cleared indications that include preventive migraine treatment and acute treatment of pain associated with migraine headache in adolescent patients age 12 and older and adult patients, along with several non-migraine headache indications. Its device format is handheld, meaning the device is manually positioned at the side of the neck during treatment.

4) Relivion MG

Comparison Fit: People comparing a prescription-based headband device format for acute migraine treatment

Access: Prescription required

Treatment Format: External combined occipital-trigeminal neurostimulation through a headband-style device

Relivion MG uses a headband-style system that stimulates trigeminal and occipital nerve branches. FDA documentation and Relivion's official materials describe Relivion MG as indicated for the acute treatment of migraine with or without aura in patients 18 years of age or older.

What Makes It Stand Out

Relivion MG stands out for its combined trigeminal and occipital stimulation format. It uses a larger headband-style format, and is listed for acute migraine treatment rather than both acute and preventive migraine indications.

5) HeadaTerm 2

Comparison Fit: People comparing a lower-cost, forehead-based OTC device format for migraine prevention labeling

Access: Available without a prescription in the U.S.

Treatment Format: Forehead-based transcutaneous electrical nerve stimulation device

HeadaTerm 2 is an FDA-cleared OTC forehead-based e-TNS device format. FDA documentation states that HeadaTerm 2 is indicated for the prophylactic treatment of episodic migraine in patients 18 years of age or older and identifies over-the-counter use. The FDA summary describes the device as delivering electrical impulses to the supraorbital and supratrochlear nerves.

What Makes It Stand Out

HeadaTerm 2 stands out for OTC access and a forehead-based format. Its FDA-cleared indication is for prophylactic treatment of episodic migraine in adults 18 years of age or older.

Comparing Device Placement and Daily Practicality

Device placement can influence how each option fits into daily routines.

• Forehead-based devices include Cefaly and HeadaTerm 2. Cefaly uses an electrode positioned on the forehead, between and just above the eyebrows, and the device attaches to the electrode. This allows hands-free use during sessions.
• Upper-arm devices include Nerivio. This format avoids head or face placement, but it depends on smartphone control and a prescription-based access pathway.
• Neck-applied devices include gammaCore. This format is handheld and requires manual positioning at the side of the neck during treatment.
• Headband-style devices include Relivion MG. This format uses a larger wearable structure and requires prescription access.
• Back-of-head magnetic stimulation devices include eNeura SAVI Dual. This format uses single-pulse transcranial magnetic stimulation and a prescription-based monthly access model.

Comparing Access Models

Access is one of the clearest practical differences across migraine devices.

OTC access options:

• CEFALY
• HeadaTerm 2

Prescription-based options:

• eNeura SAVI Dual
• Nerivio
• gammaCore Sapphire
• Relivion MG

Cefaly's advantage is that it combines OTC access with both acute and preventive adult migraine indications. HeadaTerm 2 is also OTC, but its FDA-cleared indication is prophylactic treatment of episodic migraine in adults 18 years of age or older.

Comparing Treatment Formats

Treatment session structure differs by device and should be understood according to each device’s labeling and instructions for use.

• Cefaly: 60-minute Acute program and 20-minute Prevent program
• Nerivio: 45-minute treatment session format
• gammaCore: short handheld neck-applied stimulation sessions, with dosing dependent on indication and labeling
• Relivion MG: acute treatment format using a headband-style device
• HeadaTerm 2: preventive-use labeling for episodic migraine in adults 18 years of age or older
• eNeura SAVI Dual: sTMS pulses delivered at the back of the head through a prescription access model

Cefaly’s format is especially practical for people comparing a compact, hands-free, forehead-based device that does not require a prescription and does not require monthly access to keep the device active. 

Why Cefaly Is the Strongest eNeura Alternative for Practical Access

Cefaly is the strongest overall eNeura alternative for people comparing access, practicality, ownership, and adult migraine indication breadth. It is FDA-cleared for both acute and preventive migraine use in adults, available without a prescription in the U.S., Canada, the EU, and other countries where Cefaly is sold. It is also compact, forehead-based, hands-free during sessions, and supported by app features where available.

Cefaly also avoids the access friction of prescription-based monthly device models. Its one-time purchase structure, replacement-electrode model, coaching support, HSA/FSA eligibility, and VA coverage information make it one of the most practical device options in the migraine neuromodulation category.

For a high-level comparison, Cefaly’s main differentiators are clear:

• OTC access in the U.S.
• FDA-cleared acute and preventive adult migraine indications
• Forehead-based e-TNS technology targeting the trigeminal nerve
• Hands-free treatment sessions
• Standalone device use with optional app support where available
• One-time device ownership plus replacement electrodes
• Coaching and support resources
• Refund-based 90-day satisfaction guarantee for directthe official website purchases

Preguntas frecuentes

Are there FDA-cleared migraine neuromodulation devices available without a prescription?

Yes. Cefaly and HeadaTerm 2 are FDA-cleared OTC migraine neuromodulation devices in the U.S. Cefaly is FDA-cleared for the acute treatment of migraine with or without aura in adults 18 years of age or older and for the prophylactic treatment of episodic migraine in adults 18 years of age or older. HeadaTerm 2 is FDA-cleared for the prophylactic treatment of episodic migraine in adults 18 years of age or older.

What is the main difference between Cefaly and eNeura?

Cefaly uses external trigeminal nerve stimulation through a forehead electrode, while eNeura SAVI Dual uses single-pulse transcranial magnetic stimulation applied at the back of the head. Cefaly is available without a prescription in the U.S., in Canada, the EU, and other countries, and uses a one-time device purchase model, while eNeura SAVI Dual uses prescription-based monthly access.

What is the main difference between Cefaly and HeadaTerm 2?

Both devices are OTC forehead-based options in the U.S., but their FDA-cleared indications differ. Cefaly Dual is listed for both acute migraine treatment and prophylactic treatment of episodic migraine in adults 18 years of age or older. HeadaTerm 2 is listed for prophylactic treatment of episodic migraine in adults 18 years of age or older.

Can Cefaly be used with migraine medication?

Cefaly is drug-free and does not add another medication to your routine. Talk to your healthcare provider if you have questions about using Cefaly with medications or other migraine treatments. A healthcare provider can help evaluate how a device fits into an individual migraine care plan.

Who may need individualized clinical guidance before using Cefaly?

Healthcare provider guidance is important for people who are pregnant, breastfeeding, have implanted devices, have cardiac devices, have a complex medical history, are changing medications, or are experiencing new or unusual symptoms. Device-specific contraindications, warnings, and instructions for use should guide any safety review.

How does Cefaly’s cost model compare with prescription-based migraine devices?

Cefaly uses a one-time device purchase model plus replacement electrodes. Prescription-based devices may involve monthly access, refill-based use, insurance review, or plan-specific coverage rules. Cefaly's cost structure is easier to understand upfront because device ownership and replacement supplies are separated from monthly prescription access.